Which health indicators are important to monitor for clients who are prescribed second-generation antipsychotic medications?

Choice A reason: Second-generation antipsychotics (SGAs) are strongly associated with metabolic syndrome. Standard of care guidelines, such as those from the ADA and APA, mandate regular monitoring of weight (BMI), waist circumference, blood pressure, fasting blood glucose (to screen for diabetes), and a lipid profile (to screen for dyslipidemia). These side effects contribute to the high cardiovascular mortality rate in patients with chronic mental illness. Choice B reason: While an EKG is important for specific drugs like ziprasidone, and a CBC is mandatory for clozapine, these are not the primary metabolic monitors required for the entire class of SGAs. Thyroid function is more relevant to lithium therapy. The most pervasive and consistent risks across the SGA class are the metabolic changes associated with weight gain and insulin resistance. Choice C reason: Although prolactin levels can be elevated by SGAs (especially risperidone), they are not part of the routine "metabolic" screening panel required for all clients. Similarly, while insulin levels might be elevated in insulin resistance, fasting blood glucose and HbA1c are the standardized clinical metrics used to monitor for the onset of drug-induced type 2 diabetes mellitus. Choice D reason: A complete metabolic profile (CMP) and liver/kidney function tests are standard for many medications to monitor clearance and electrolyte balance. However, they do not capture the specific "metabolic" triad of obesity, diabetes, and dyslipidemia that defines the primary safety concern for patients on second-generation antipsychotic agents, making Choice A the most specific and correct answer.